Latest Bosentan Stories

NEW YORK, Sept. 25, 2012 /PRNewswire/ -- IntraLinks® (NYSE: IL), a leading, global technology provider of inter-enterprise content management and collaboration solutions, today announced that Actelion Pharmaceuticals Ltd, an Allschwil/Basel, Switzerland headquartered biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments to serve unmet medical needs, has selected IntraLinks Connect(SM) to streamline their documentation...

MALVERN, Pa. and LAVAL, Quebec, July 9, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Actelion Pharmaceuticals Canada Inc. announced today that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX(®) (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren's contracture in adults with a palpable cord in Canada. (Logo:...

PITTSBURGH and TORONTO, June 6, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Canadian subsidiary, Mylan Pharmaceuticals ULC, has received approval from Health Canada for Mylan-Bosentan Tablets, 62.5 mg and 125 mg. Mylan-Bosentan is the generic version of Actelion Pharmaceuticals Ltd.'s Tracleer(®), used for the treatment of pulmonary arterial hypertension(1). According to IMS Health, Bosentan Tablets had Canadian sales of approximately $37.8 million(2)...

BRUSSELS, February 29, 2012 /PRNewswire/ -- In the news release, "'Breathtaking' Campaign Launched to Raise Awareness of Deadly Lung Disease, Pulmonary Hypertension, on Rare Disease Day" issued on 28 Feb 2012 23:01 GMT, by Pulmonary Hypertension Association Europe and Bayer HealthCare over PR Newswire, we are advised by a representative of the company that a new link fits into the following passage of text: "Footage of the 'Breathtaking' campaign events will be available at the following...

BRUSSELS, February 28, 2012 /PRNewswire/ -- Events held across Europe to highlight little-known, life-threatening condition that takes breath away[1] A campaign has been launched today, on Rare Disease Day, to raise awareness of the little known but deadly disease, pulmonary hypertension (PH) and in particular, a rare form called pulmonary arterial hypertension (PAH). Events are taking place across Europe, with a key event in...

MALVERN, Pa., and ALLSCHWIL/BASEL, Switzerland, Feb. 23, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Actelion Pharmaceuticals Ltd. (SWX: ATLN.S) announced today that they have entered into a long-term partnership for the development, supply and commercialization of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the potential treatment of Dupuytren's contracture and Peyronie's disease. Under the terms of the...

EAST HANOVER, N.J., Sept. 25, 2011 /PRNewswire/ -- Novartis announced new data today from the pivotal Phase III IMPRES clinical trial showing that the investigational therapy QTI571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH) after 24 weeks compared with placebo(1). Evidence indicates that QTI571 targets an underlying cause of PAH by counteracting uncontrolled growth of arterial smooth muscle cells(2). The IMPRES study met its...

SILVER SPRING, Md., June 6, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH). Preliminary analysis demonstrates that the trial has met its primary endpoint. FREEDOM-M was a randomized,...

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Aires Pharmaceuticals, Inc. today announced the hiring of Ed Parsley, D.O. as Chief Medical Officer. Dr. Parsley will fill a key role on Aires' leadership team and will be responsible for all clinical development activities for Aironite(TM), the company's lead product for treatment of pulmonary arterial hypertension (PAH). Dr. Parsley joins Aires from Pfizer where he was the Clinical Lead for ongoing clinical trials for Revatio (Sildenafil), Pfizer's...

WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc. will be jointly presenting a thematic poster at the "Novel Therapeutics in Pulmonary Fibrosis" session at the 2011 American Thoracic Society (ATS) International Conference in Denver, Colorado on May 18, 2011. The poster entitled Differing Effects of Ambrisentan and Bosentan on Pulmonary Fibrosis and Lung Mechanics Following Bleomycin Instillation will be presented by John Liles, PhD of...